http://orcid.org/0000-0003-0735-2861
References
- Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–20.
- Bednarczyk D, Boiselle C. (2016). Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III. Xenobiotica 46:457–66.
- Benet LZ. (2010). Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. Basic Clin Pharmacol Toxicol 106:162–7.
- Di L, Whitney-Pickett C, Umland JP, et al. (2011). Development of a new permeability assay using low-efflux MDCKII cells. J Pharm Sci 100:4974–85.
- Dickson CJ, Hornak V, Bednarczyk D, Duca JS. (2019). Using membrane partitioning simulations to predict permeability of forty-nine drug-like molecules. J Chem Inf Model 59:236–44.
- Fu D, Zhou J, Zhu WS, et al. (2014). Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering. Nat Chem 6:614–22.
- Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL. (2008). Lysosomal trapping of amodiaquine: impact on transport across intestinal epithelia models. Biopharm Drug Dispos 29:324–34.
- Huang Y, Okochi H, May BC, et al. (2006). Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos 34:1136–44.
- Kazmi, F, Hensley, T, Pope, C, et al. (2013). Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metabolism and Disposition: The Biological Fate of Chemicals 41:897–905. doi:10.1124/dmd.112.050054
- Killinger JM, Weintraub HS, Fuller BL. (1979). Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride. J Clin Pharmacol 19:211–8.
- Kunze A, Poller B, Huwyler J, Camenisch G. (2015). Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins. Drug Metab Pers Ther 30:175–88.
- Mindell JA. (2012). Lysosomal acidification mechanisms. Annu Rev Physiol 74:69–86.
- Nadanaciva S, Lu S, Gebhard DF, et al. (2011). A high content screening assay for identifying lysosomotropic compounds. Toxicol in Vitro 25:715–23.
- Peng B, Lloyd P, Schran H. (2005). Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879–94.
- Shannon JA, Earle DP, Brodie BB, et al. (1944). The pharmacological basis for the rational use of atabrine in the treatment of malaria. J Pharmacol Exp Ther 81:307–30.
- Skolnik S, Lin X, Wang J, et al. (2010). Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay. J Pharm Sci 99:3246–65.
- Varma MV, Steyn SJ, Allerton C, El-Kattan AF. (2015). Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS). Pharm Res 32:3785–802.
- Wohnsland F, Faller B. (2001). High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem 44:923–30.
- Yeung PK, Hubbard JW, Korchinski ED, Midha KK. (1993). Pharmacokinetics of chlorpromazine and key metabolites. Eur J Clin Pharmacol 45:563–9.